A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules by Zhang, Andrew X. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Remote Arene-Binding Site on Prostate Specific Membrane
Antigen Revealed by Antibody-Recruiting Small Molecules
Citation for published version:
Zhang, AX, Murelli, RP, Barinka, C, Michel, J, Cocleaza, A, Jorgensen, WL, Lubkowski, J & Spiegel, DA
2010, 'A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-
Recruiting Small Molecules' Journal of the American Chemical Society, vol. 132, no. 36, pp. 12711-12716.
DOI: 10.1021/ja104591m
Digital Object Identifier (DOI):
10.1021/ja104591m
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of the American Chemical Society
Publisher Rights Statement:
Copyright © 2010 by the American Chemical Society. All rights reserved.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
A Remote Arene-Binding Site on Prostate Specific Membrane
Antigen Revealed by Antibody-Recruiting Small Molecules
Andrew X. Zhanga, Ryan P. Murellia, Cyril Barinkab, Julien Michela, Alexandra Cocleazaa,
William L. Jorgensena, Jacek Lubkowskic, and David A. Spiegela,d,*
aDepartment of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven,
CT 06510-8107 USA
bLaboratory of Structural Biology, Institute of Biotechnology AS CR,v.v.i., 14200 Prague 4, Czech
Republic
cMacromolecular Crystallography Laboratory, 539 Boyles Street, National Cancer Institute at
Frederick, Frederick, MD, 21702, USA
dDepartment of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New
Haven, CT 06520 USA
Abstract
Prostate specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase
overexpressed in many forms of prostate cancer. Our laboratory has recently disclosed a class of
small molecules, called ARM-Ps (antibody-recruiting molecule targeting prostate cancer) that are
capable of enhancing antibody-mediated immune recognition of prostate cancer cells.
Interestingly, during the course of these studies, we found ARM-Ps to exhibit extraordinarily high
potencies toward PSMA, compared to previously reported inhibitors. Here, we report in-depth
biochemical, crystallographic, and computational investigations which elucidate the origin of the
observed affinity enhancement. These studies reveal a previously unreported arene-binding site on
PSMA, which we believe participates in an aromatic stacking interaction with ARMs. Although
this site is composed of only a few amino acid residues, it drastically enhances small molecule
binding affinity. These results provide critical insights into the design of PSMA-targeted small
molecules for prostate cancer diagnosis and treatment; more broadly, the presence of similar
arene-binding sites throughout the proteome could prove widely enabling in the optimization of
small-molecule–protein interactions.
Introduction
Prostate cancer is a major public health threat against which currently available therapeutic
strategies are often ineffective.1,2 Our laboratory has recently disclosed a class of small
molecules, called ARM-Ps (antibody-recruiting molecule targeting prostate cancer) that are
capable of enhancing antibody-mediated immune recognition of prostate cancer cells.3,4
ARM-Ps accomplish this by binding simultaneously to prostate-specific membrane antigen
(PSMA),5 a membrane-bound glycoprotein that is overexpressed on prostate cancer cells,
and to anti-dinitrophenyl (anti-DNP) antibodies, which are present endogenously in the
human bloodstream (Figure 1A and B).6 PSMA, which is also known as glutamate
carboxypeptidase II (GCPII), is a well-studied molecular signature of prostate cancer cells,
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and has been exploited as a target in both therapeutic and diagnostic strategies for patients
with prostate cancer.7–11 PSMA possesses glutamate carboxypeptidase activity, and
numerous studies have focused on the identification of small molecules capable of inhibiting
this enzyme.12–17 ARM-Ps belong to a class of glutamate urea compounds capable of
inhibiting PSMA with high potency.14
During the course of developing ARM-Ps, we observed that bifunctional DNP-containing
conjugates were strikingly more potent than the parent glutamate urea compounds from
which they were derived. Furthermore, we also noted that potency increases were correlated
to the length of the linker regions connecting the two poles of the molecule. Here we provide
a molecular basis for these findings, which involves the disclosure of a previously
unreported arene-binding site on PSMA. These conclusions are supported by extensive
biochemical, crystallographic, and computational studies.
Results and discussion
Dependence of linker length on binding affinity
To evaluate in detail the effect of linker length on PSMA binding affinity, we prepared
various derivatives of ARM-P (Table 1, 1–12). These compounds consist of glutamate ureas
linked to DNP or methoxy groups by oxyethylene moieties of varying lengths. They are
named ARM-Px and MeO-Px, respectively, wherein “x” corresponds to the number of
oxyethylene units in the linker. Evaluation of these compounds for their ability to inhibit
PSMA activity proved quite revealing.3 In all cases, ARM-P derivatives were found to
possess Ki values lower in magnitude than their counterparts lacking DNP (compounds 1–7
versus 8–12). In some cases, the affinity difference was up to two orders of magnitude
(compound 3 versus 9). This result indicated to us that perhaps the DNP function itself
might be playing a role in binding PSMA. Such a hydrophobic interaction involving an
aromatic ring and PSMA was not completely unexpected given the proximity of the
glutamate-urea binding site to a known hydrophobic pocket in PSMA.18,19 Indeed,
inhibitors containing hydrophobic functionality distal to the glutamic acid moiety have
exhibited high potency against PSMA.13,20,21
A model involving binding of the DNP moiety to the hydrophobic pocket adjacent to the S1
site did not explain the decrease in affinity between ARM-P2 and derivatives with shorter
oxyethylene linkers (i.e., ARM-P0 and ARM-P1). Indeed, one would expect ARM-P0 and
ARM-P1 to exhibit enhanced potency versus ARM-P2 because of the close proximity of the
accessory hydrophobic pocket to the P1’ glutamate binding cavity. The opposite trend
suggested perhaps the presence of an alternative hydrophobic binding site, situated at a
substantial distance away from this cavity. This hypothesis is supported by observations in
related systems in which bifunctional ligands bind proteins at two remote sites. In such
systems, an ideal linker length between binding poles is required for maximum affinity;
shorter linkers are unable to form optimal interactions in both binding sites, while longer
linkers pay a relatively high entropic penalty upon bivalent binding without any
compensatory enthalpic benefit.22–25
Notably, compounds within the MeO-P series (8–12) containing relatively short linkers all
bind PSMA with comparable affinity. The presence of linkers consisting of 8 oxyethylene
groups or longer appears to inhibit compound binding, perhaps because bulky PEG chains
prevent access of the glutamate urea moiety to its binding site on PSMA.26 The increased
sensitivity of ARM-P derivatives to changes in linker length as compared to MeO-P
compounds suggests that factors other than simple steric bulk are operating for the ARM-Ps.
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Structure–activity studies: effect of varying aromatic groups on binding affinity
To test further our model for bidentate binding, we set out to probe the impact of the phenyl
ring substituent on inhibitor potency. We therefore synthesized analogues of ARM-P2
replacing the DNP moiety with a range of electronically distinct aromatic species (3, 13–17,
Table 2). As shown, these analogues included nitrophenyl (ortho and para to the linker), p-
methoxyphenyl, phenyl, and cyclohexyl derivatives. Consistent with the hypothesis that the
DNP moiety occupies a novel binding site, profound changes in affinity were observed in
this series. Interestingly, the parent dinitrophenyl-containing compound (ARM-P2)
possessed the highest potency of all the analogues tested (Ki = 24 pM), and removal of nitro
groups led to three-fold decreases in affinity in the p-nitrophenyl (13) and o-nitrophenyl (14)
analogues (Ki = 60 and 78 pM, respectively). The similarities between these analogues
suggests that inhibitor potency is dictated by electronic rather than steric effects. Phenyl (15)
and methoxyphenyl (16) analogues proved an additional order of magnitude less potent than
mononitrated derivatives (Ki = 730 and 970 pM, respectively), and the cyclohexyl-
substituted derivative (17) proved yet another order of magnitude worse than the least potent
aryl compounds (Ki = 15.1 nM). This may result from the enhanced steric bulk of the
cyclohexyl substituent versus planar arenes.
To examine the relationship between arene electronics effects and PSMA inhibitory
potency, we performed semiempirical calculations of arene LUMO energies using the
PDDG/PM3 method implemented in the BOSS software package.27,28 An excellent
correlation was observed between the LUMO energies of aromatic substituents and
experimentally determined Ki values (Figure 2). Electron poor aromatic rings are expected
to experience strong π-stacking interactions with electron-rich arenes,29,30 suggesting that
such interactions may be dominant in dictating binding affinity in this system. These results
are strongly indicative of multisite binding in the ARM-P series, and led us to test this
hypothesis further using X-ray crystallography.
Crystallographic Studies
Initial refinement and analysis—Crystal structures were determined for PSMA in
complex with ARM-P ligands containing 2, 4, and 8 oxyethylene units in the linker region
(3, 4, and 6) and with MeO-P4 (10), which lacks the DNP moiety, and were refined at the
resolution of 1.69 Ǻ, 1.59 Ǻ, 1.59 Ǻ, and 1.78 Ǻ, respectively. Individual compounds were
fit into the positive peaks on the difference Fo-Fc electron density map in the final stages of
refinement. For all four inhibitors, clear interpretable densities were observed for the C-
terminal part encompassing the P1’ glutarate, the urea linkage, the lysine linker and the
triazole ring. Although density corresponding to the DNP phenyl ring is defined in all ARM-
P complexes, density corresponding to the nitro groups is absent suggesting that the DNP
moiety is present in at least two different conformations. Also, electron density peaks
corresponding to the poly-oxyethylene linker were absent from all complexes, consistent
with a lack of intermolecular contacts between this flexible element and the protein.
Models of ARM-P2, ARM-P4, and ARM-P8 in complex with PSMA, built from the
electron density map, are depicted in Figure 3. Despite the attachment of large oxyethylene
linkers, the glutamate urea portions of all inhibitors interact with the protein active site in a
fashion reminiscent of previously reported complexes with urea13,14,18 and phosphonate31
inhibitors, and the substrate N-acetyl-aspartyl-glutamate (NAAG).32 In all structures,
positioning of the P1’ glutarate is enforced by H-bonds (indicated as dashed lines) with
Arg210, Asn257, Tyr552, Lys699, Tyr700, and active-site water molecules, and
hydrophobic interactions with the side chains of Phe209 and Leu428. The ureido nitrogen
atoms serve as H-bond donors in interactions with Glu424 and the Gly518 main chain
carbonyl, and the carbonyl oxygen makes contacts with both the catalytic zinc atom and
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Tyr552, and His553. The P1 α-carboxylate in all inhibitors structurally overlaps with the
equivalent groups of previously reported complexes, and is held in place by interactions
with an arginine-rich patch (Arg463, Arg534, Arg536) along with H-bonding contacts to
Asn519, the Ser517 main-chain carbonyl, and water molecules.18,19
Discovery of an arene-binding cleft—A key site of interaction between PSMA and all
ARM-P derivatives is the triazole ring, which was observed to pack against the side chains
of Tyr552 and Tyr700 in all complexes (Figure 3). The steric hindrance caused by the
oxyethylene linker emanating from the triazole ring prevents closure of the enzyme’s
entrance lid (amino acids Trp541 – Gly548), as observed for PSMA complexes with smaller
ligands.19 A key consequence of the entrance lid’s open conformation is the revelation of a
previously unreported binding cleft for the DNP ring (Figure 4).19
The arene-binding region, formed from the indole group of Trp541 and the guanidinium
group of Arg511 holds the DNP ring in close contact with these groups at distances of 3.1 Å
and 3.9 Å, respectively. The bottom of the cleft is lined by the Arg463 side chain.
Positioning of the phenyl ring creates a plane virtually parallel to both indole and
guanidinium functionalities, suggesting that simultaneous π-cation (DNP-Arg511) and π-
stacking (DNP-Trp541) interactions may both contribute to inhibitor binding.34,35
Critically, the arene-binding region is only revealed upon opening of the entrance lid (Figure
4B); closure of the entrance lid, as in the overlaid complex between PSMA and the small
urea-based inhibitor DCIBzL,33 would lead to significant steric overlap with the triazole
moiety as well as closure of the arene-binding site (Figure 4C). Thus, the protein is capable
of adopting two separate conformations, each suited to accommodate high-affinity binding
interactions with distinct classes of glutamate-urea inhibitors.
A key structural feature was observed in the MeO-P4 complex (Figure 5). Here, unlike in
the ARM-P complexes, Trp541 exists in two distinct conformations. The non-stacking
conformation is rotated approximately 4 Å from what is seen in ARM-P complexes, and
blocks the arene-binding groove. The conformational flexibility exhibited by Trp541 in the
PSMA/MeO-P4 complex suggests that when present, the dinitroarene stabilizes the side
chain indole moiety via π-stacking, as implied by the ARM-P structures depicted above.
Taken together, these data provide strong support for a model in which ARM-Ps bind PSMA
through interactions at both the enzyme active site and at a newly reported arene-binding
cleft.
Notably, the complex between PSMA and MPE,36 a methotrexate-derived phosphonate,
was also shown to possess an open entrance lid like the complexes disclosed herein.19 It
was concluded from the PSMA/MPE complex that the protein’s ability to adopt an open
conformation serves to enable its binding to relatively large substrates, such as folyl-poly-γ-
glutamates. One might imagine that the revelation of an arene-binding site upon opening of
the entrance lid might serve to enhance affinity for these arene-containing enzyme
substrates. Interestingly, however, the pendant pteroyl ring in the MTE complex was not
observed to interact with the PSMA arene-binding cleft, perhaps due to its relatively short
linkage to the zinc-binding phosphonate region. The observations reported herein suggest
that perhaps larger natural poly-γ-glutamate substrates are able to make use of the arene-
binding site, however further studies are necessary to test this possibility.
Molecular dynamics (MD) simulations
To clarify the nature of the protein-ligand interactions in the ARM-P complexes, explicit
solvent molecular dynamics (MD) simulations were carried out using crystallographic data
for PSMA complexes with ARM-P0, ARMP-P2, ARM-P4, ARM-P8 and MeO-P0. Each
protein-ligand complex was modeled with the OPLS-AA force field,37 embedded in a
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triclinic box of TIP3P water molecules.38 Dynamics were simulated for 50 ns using the
Desmond software package.39
These simulations revealed a number of noteworthy features (see Supporting Information for
video files for all simulations). Although the PSMA active site and glutamate urea moieties
are fairly rigid throughout the timescale of MD simulations, distal protein-ligand
interactions exhibit highly dynamic behavior. For example, the simulation of the MeO-P0–
PSMA complex revealed that the arene-binding site is unstable in the absence of DNP;
Trp541 tends to rotate toward Arg511, thus obscuring the arene-binding site (Figure 6,
panels a–c). This observation directly correlates with the disorder in Trp541 observed in the
MeO-P4–PSMA crystal structure (Figure 3). Furthermore, the PEG moieties in all
complexes are highly dynamic and do not seem to form specific interactions with PSMA,
suggesting that these make minimal enthalpic contributions to binding affinity. These
observations also explain the absence of electron density corresponding to linker regions in
all crystal structures.
By far the most stable intermolecular contact in the arene-binding site in ARM-P–PSMA
complexes is the stacking interaction between DNP and Trp541. For all ARMs, the DNP
moieties participate in face-to-face interactions with Trp541 side chain indole moieties for
significant time periods throughout MD simulations. Simulations of the ARM-P0–PSMA
complex revealed a remarkable level of flexibility in the triazole-alkyl region, which enables
π-stacking contacts in the arene-binding site to remain intact even in the absence of an
oxyethylene linker (Figure 6, panels d–f). When stacked with the Trp541 side chain indole,
the DNP ring is observed to rotate in-plane, supporting the hypothesis that the lack of well
defined electron density corresponding to nitro groups in crystal structures is due to the
presence of multiple arene conformations. However, in all ARM-P complexes, the nitro
groups in the DNP ring are frequently observed pointing toward the Arg463 side chain
guanidinium group, suggesting possible hydrogen bonding or electrostatic interactions
between these groups. Furthermore, although crystallographic data support a role for π-
cation interactions with Arg511 in the arene-binding site, this residue is highly disordered in
MD simulations, and does not form long-lived contacts with the ligand. This observation is
consistent with the data presented in Table 2 and Figure 2, which suggest that cation-π
interactions play a relatively minor role versus π-stacking interactions in stabilizing these
systems.
Notably, during the course of MD simulations for both ARM-P2 (panels g-i) and ARM-P8
(panels m-o), the DNP ring dissociates from the arene-binding cleft, whereas this interaction
remains intact in the ARM-P4 simulation (panels j–l). Taken together, these data suggest
that the DNP–Trp541 interactions are relatively weak. Interestingly, the contact with Trp541
reforms rapidly during the simulations of ARM-P2, but not ARM-P8; this may either reflect
a higher entropic penalty associated with bivalent binding because of the longer linker
group, or the tendency of the linker to occupy the arene-binding site, thus preventing the
DNP group’s return to Trp541.22–25 Additional studies to clarify the contribution of the
linker group to the binding thermodynamics of the ARM-P ligands would be desirable.
From a functional standpoint, the propensity of ARM-P8 to disengage from the PSMA
arene-binding site enables it to form ternary complexes with prostate cancer cells and
antibodies, which is critical to its cytotoxic activity.3 However, this functionality comes at
the expense of PSMA binding affinity. Furthermore, the model reported herein suggests the
possibility of ultra high-affinity ARM-P analogues capable of interacting simultaneously
with the PSMA arene-binding site and anti-DNP antibodies.
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Conclusion
Here we detail the discovery of an arene-binding site on prostate-specific membrane antigen
(PSMA), which gives rise to unusually high affinity binding interactions with designed
bifunctional antibody-recruiting small molecules (ARMs). Our conclusions are supported by
extensive crystallographic, biochemical, and computational data, which, taken together,
strongly suggests a model in which bidentate binding of ARM-Ps to PSMA leads to
substantial increases in inhibitor potency. The serendipitous nature of the discovery reported
herein along with the relative simplicity of the PSMA arene-binding site – which consists
merely of three amino acids only one of which (Trp541) is responsible for affinity
enhancement – suggest that low-affinity binding sites for arenes could be quite prevalent
among proteins. Along these lines, it is well-documented that a large proportion of
circulating immunoglobulin possess high-affinity binding activity against nitroarene ligands,
41 and between 1 and 10% of myeloma proteins bind nitrophenyl ligands.42 The possibility
that such binding sites arise from conserved folds within immunoglobulin domains has been
suggested,43 however, this trend may also result from the unique immunogenicity of
nitroarenes,44,45 a property that has also been attributed to their propensity to form
hydrophobic contacts with proteins.44 In either case, although structural data exists
demonstrating the unique propensity of nitroarenes to engage in π-stacking interactions with
aromatic amino acid side chains,46,47 the proteomic prevalence of nitroarene-binding
motifs has not been systematically explored. The widespread existence of such binding sites
could enable facile optimization of small molecule ligands for proteins identified through
high-throughput screening, and could find ready utility in fragment-based approaches to
inhibitor design.48
Although underexplored, strategies that utilize small molecules to enhance recognition of
pathogens by the human immune system promise to leverage the strengths of both antibody-
and small-molecule-based therapeutic approaches. The results reported herein suggest the
possibility for improving such technologies for treating prostate cancer. For example, ultra-
high-affinity ARM-Ps could be constructed by exploiting the presence of the arene-binding
site in PSMA and converting the highly flexible first-generation ARM-Ps into more rigid
scaffolds. More broadly, the high-level expression of PSMA (GCPII) on prostate cancer cell
surfaces and on tumor neovasculature,49 as well as its putative role in the pathophysiology
of schizophrenia,50 have rendered it an extremely useful and popular target for inhibitor
design. The results presented herein therefore could substantially impact the development of
effective diagnostic and therapeutic approaches for patients suffering from cancer and other
diseases.
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Figure 1.
Structure and Function of ARM-Ps (antibody-recruiting molecules targeting prostate
cancer). (A) ARM-Ps recruit anti-DNP antibodies to PSMA-expressing prostate cancer cells,
and thereby bring about immune-mediated cytotoxicity. (B) ARM-Ps are bifunctional and
consist of an antibody-binding terminus (ABT), a linker region, and a cell-binding terminus
(CBT).
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Figure 2.
Correlation between Ki values and ELUMO of aromatic ring component of ARM-P analogue.
Measured Ki values (mean of triplicate experiments ± standard deviation) are plotted versus
PDDG/PM3 LUMO energies calculated using the BOSS software package.
Zhang et al. Page 11
J Am Chem Soc. Author manuscript; available in PMC 2011 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Close-up of PSMA active site bound to bifunctional glutamate urea inhibitors ARM-P2
(gold), ARM-P4 (grey), and ARM-P8 (blue). Structures were superimposed on with
corresponding (or equivalent) Cα atoms. Inhibitors are shown in stick representation and
protein residues are shown as lines. Hydrogen bonding interactions are indicated by dashed
lines. The zinc ions and chloride ion in the active site are labeled as grey and green dotted
spheres, respectively, and water molecules are depicted as red spheres. In both protein and
inhibitor structures, carbon atoms are colored as indicated above, and other atoms are
colored red (oxygen), and blue (nitrogen).
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Figure 4.
The PSMA/ARM-P2 complex reveals a previously unreported arene-binding cleft. (A)
Global view of PSMA with a close-up of arene-binding site. Residues making up the arene-
binding cleft are labeled in cyan. The entrance lid (residues 542–548), which resides in an
open conformation in the ARM-P2 complex, is indicated as a red loop. Overlaid on this
complex is the entrance lid in its closed conformation (colored blue), which would come
into steric conflict with the linker region of the inhibitor. (B and C) Close-up images of the
urea binding sites in structures containing both open and closed entrance loops (colored in
blue). Residues forming the DNP binding site (W541, R511, and R463) are colored red. In
all panels, structural data for PSMA with a the closed entrance lid comes from the complex
with the small urea-based inhibitor DCIBzL (PDB ID – 3IWW).33 The zinc ions in the
active site are labeled as orange spheres and the ARM-P2 carbons are colored gold. The
DCIBzL carbons in B and C are colored purple.
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Figure 5.
Close-up view of the active site of PSMA bound to MeO-P4. Hydrogen bonding interactions
are indicated by dashed lines. The zinc ions in the active site and adjacent chloride ion are
labeled as grey and green dotted spheres, respectively, and water molecules are depicted as
red spheres. In both protein and inhibitor structures, carbon atoms are colored in olive, and
other atoms are colored red (oxygen), and blue (nitrogen).
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Figure 6.
Selected snapshots from the MD simulations of PSMA/ARM-P complexes. The ligands are
represented in colored sticks, Arg463, Arg511 and Trp541 are represented in orange sticks.
Figure created with the program VMD.40
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Table 1
Linker length dependence on PSMA inhibitory potency.
Compound X n IC50 (nM)b Ki (nM)c
1, ARM-P0 DNPa 0 1.76 ± 0.41 0.078 ± 0.018
2, ARM-P1 DNP 1 1.05 ± 0.11 0.047 ± 0.005
3, ARM-P2 DNP 2 0.54 ± 0.18 0.024 ± 0.008
4, ARM-P4 DNP 4 0.46 ± 0.18 0.020 ± 0.008
5, ARM-P6 DNP 6 2.29 ± 0.60 0.101 ± 0.027
6, ARM-P8 DNP 8 3.29 ± 1.14 0.145 ± 0.050
7, ARM-P12 DNP 12 37.3 ± 16.2 1.65 ± 0.72
8, MeO-P0 OMe 0 30.5 ± 12.1 1.35 ± 0.54
9, MeO-P2 OMe 2 40.8 ± 9.4 1.81 ± 0.42
10, MeO-P4 OMe 4 30.2 ± 14.4 1.34 ± 0.64
11, MeO-P8 OMe 8 131.0 ± 57.6 5.79 ± 2.54
12, MeO-P12 OMe 12 165.2 ± 58.9 7.30 ± 2.60
a
b
IC50 values represent the mean of triplicate experiments.
c
Ki values were calculated from IC50 and Km values using the Cheng-Prusoff equation as described in the supporting information.
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Table 2
Dependence of Ki on substituents and electronics of aromatic ring.
Compound X ELUMO (eV)a IC50 (nM)b Ki (nM)c
3, ARM-P2 DNP −1.44 0.54 ± 0.18 0.024 ± 0.008
13 o-NO2-Ph −0.92 1.78 ± 0.15 0.078 ± 0.007
14 p-NO2-Ph −0.91 1.36 ± 0.18 0.060 ± 0.008
15 Ph 0.50 16.6 ± 6.3 0.73 ± 0.28
16 p-MeO-Ph 0.43 21.9 ± 9.9 0.97 ± 0.44
17 Cyclohexyl N/A 342.3 ± 170.5 15.1 ± 7.5
a
ELUMO energies of arene rings (XŠNHMe) were calculated using the PDDG/PM3 method implemented in the BOSS software package, and
reported in electron-volts as detailed in the Supporting Information.
b
IC50 values represent the mean of triplicate experiments.
c
Ki values were calculated using IC50 and Km values via the Cheng-Prusoff equation as outlined in the supporting information. A Km value of
925 nM was used in these calculations.
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